Skin-Expressing IncRNAs in Inflammatory Responses

Alanna Shefler1, Matthew T. Patrick1, Rachael Wasikowski1, Jiahan Chen2, Mrinal K. Sarkar1, Johann E. Gudjonsson1 and Lam C. Tsoi1,2,3*

1Department of Dermatology, University of Michigan Medical School, Ann Arbor, MI, United States, 2Department of Biostatistics, University of Michigan, Ann Arbor, MI, United States, 3Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, United States

Long non-coding RNAs (IncRNAs) have attracted attention for their potential roles in modulating keratinocyte differentiation and inflammatory response; however, for many identified skin-expressing IncRNAs, there is no comprehensive characterization regarding their biological roles. In addition, the reported expression profiles for IncRNAs can be ambiguous due to their low-expressing nature. The objective of this review is to utilize large scale genomic data to characterize the prominent skin-expressing IncRNAs, aiming to provide additional insights for their potential roles in the pathology of inflammatory skin of psoriasis and atopic dermatitis by integrating in vitro and in vivo data. We highlighted the different skin-expressing IncRNAs, including H19, which is significantly down-regulated in lesional skin of AD/psoriasis and upon cytokine stimulation in keratinocytes; it is also negatively correlated with CYP1A1 (r = -0.75, p = 8 × 10^-73), a gene involved in drug metabolism and skin barrier homeostasis, in keratinocytes. In addition, SPRR2C, a potential regulator that modulates IL-22 stimulation, was upregulated in both atopic dermatitis and psoriasis lesional skin and was also downstream of the IL-17A and IL-17 + TNF signaling in keratinocytes. Using scRNAseq, we further revealed the cell type specificity of IncRNAs, including basal-expressing nature of H19 in the epidermis. Interestingly, instead of having cell type specific expression profile, we found few IncRNAs that are express across different cell types in skin, including MALAT1, NEAT1, and GAS5. While IncRNAs in general have lower expression, our results combining in vitro and in vivo experimental data demonstrate how some of these IncRNAs can play mediator roles in the cytokine-stimulated pathway.

Keywords: IncRNA, atopic dermatitis, psoriasis, keratinocyte, scRNA sequencing

REVIEW

Long non-coding RNA (IncRNA) is a class of RNA that does not have protein-coding ability and exhibits its functions as RNA (Derrien et al., 2012; Duan et al., 2020). IncRNAs are >200 nucleotides in length and are commonly located in the chromatin and nucleus (Derrien et al., 2012; Hombach and Kretz, 2013). With the advent of next generation sequencing technologies that enable the detection of low-expressing transcripts, a substantial number of novel IncRNAs have been unraveled. According to the GENCODE consortium (Derrien et al., 2012; Harrow et al., 2012), there were approximately 9,640 IncRNAs in 2010 in human (version 7). In the latest version (v38) released in 2021, the number of IncRNAs approximately doubled with a report of 17,944 IncRNAs (Frankish et al., 2021). NONCODE, a comprehensive IncRNA resource for plants and animals, has reported...
TABLE 1 | The fold change for the notable lncRNAs that play roles in skin biology and/or diseases. Bold numbers denote FDR ≤0.05. Red results denote at least 1.5-fold change when comparing against control/unstimulated conditions. Expression in inflammatory skin disease represents findings in lesional skin of atopic dermatitis/psoriasis patients compared to control without skin disease.

| lncRNA | Cell type detected | Expression in inflammatory skin disease | Expression in cytokine stimulated keratinocytes | Role |
|-------|-------------------|------------------------------------------|-----------------------------------------------|------|
|       |                   | AD | Pso | IFNa | IFNg | IL4 | IL13 | IL17A | IL17 | TNFa | + |
| DANCR | KC                | 1.16 | 1.88 | 0.92 | 0.73 | 0.99 | 0.99 | 1.02 | 0.88 | 0.89 | |
| TINCR | KC                | 0.67 | 0.65 | 1.00 | 0.68 | 1.09 | 1.07 | 0.97 | 0.77 | 0.94 | |
| H19   | KC                | 0.31 | 0.05 | 0.85 | 0.71 | 0.82 | 0.94 | 0.92 | 0.71 | 0.89 | |
| NEAT1 | Psoriatic Epidermis | 1.14 | 1.44 | 0.97 | 0.74 | 0.96 | 0.91 | 1.02 | 0.97 | 0.93 | |
| RNU1-1| KC                | NA | 1.63 | 1.01 | 1.00 | 1.00 | 1.01 | 1.00 | 1.01 | 1.00 | |
| LUC1  | KC                | 1.76 | 2.97 | 0.60 | 0.68 | 0.71 | 0.76 | 0.77 | 0.72 | 0.71 | |
| SPRR2C| KC                | 8.51 | 245.06 | 1.01 | 1.23 | 0.87 | 0.96 | 1.14 | 6.92 | 1.14 | |
| GAS5  | Psoriatic Epidermis | NA | 1.06 | 0.98 | 0.83 | 0.96 | 0.97 | 0.96 | 0.92 | 0.90 | |
| MALAT1| Psoriatic Epidermis | 1.08 | 1.02 | 1.02 | 0.76 | 0.94 | 1.07 | 1.03 | 1.12 | 0.98 | |

>170,000 transcripts from 96,000 lncRNAs (Fang et al., 2018). Different studies have revolutionized our understanding of lncRNAs as exhibiting significant regulatory roles rather than being transcriptional waste products (Hombach and Kretz, 2013), and have demonstrated that lncRNAs exhibit stronger tissue-specific expression patterns compared to protein-coding genes (Derrien et al., 2012). LncRNAs have attracted attention due to their role in gene regulatory processes, maintaining normal tissue homeostasis, and transition to diseased states (Hombach and Kretz, 2013; Tsoi et al., 2015). They have been shown to modulate epigenetic regulation of chromatin (Rinn et al., 2007; Gupta et al., 2010; Tsai et al., 2010; Heo and Sung, 2011; Wang et al., 2011; Grote et al., 2013; Hombach and Kretz, 2013; Tsoi et al., 2015), as well as participating in promoter-specific gene regulation (Hombach and Kretz, 2013; Tsoi et al., 2015; Duan et al., 2020), X-chromosome inactivation (Tian et al., 2010; Hombach and Kretz, 2013; Tsoi et al., 2015; Duan et al., 2020), and imprinting (Lee and Bartolomei, 2013). Therefore, they are associated in various diseased states, such as neurodegenerative conditions (Wapinski and Chang, 2011), susceptibility to infection (Gomez et al., 2013), and different types cancers (Huarne et al., 2010; Prensner et al., 2011; Maruyama and Suzuki, 2012).

Skin diseases are the fourth most common cause of illness, whereby up to 33% of the population is affected (Bickers et al., 2006; Hay et al., 2014; Hay et al., 2015; Tizek et al., 2019). Many of these diseases display strong inflammatory components whose mechanisms have not been fully explained. Recent genomic studies highlight how multiple lncRNAs can be implicated in key roles for epidermal homeostasis, transition to disease state, and stress response (Hombach and Kretz, 2013; Tsoi et al., 2015) (Table 1; Supplementary Table S1). Using RNA sequencing, previous work has revealed that DANCR (anti-differentiation non-coding RNA) is significantly downregulated during terminal differentiation (Huarne et al., 2010; Kretz et al., 2012), and indicates its functional role in the transition from non-differentiated to differentiated cells (Huarne et al., 2010). DANCR may also repress differentiation of osteoblasts and keratinocyte progenitors by associating with methyltransferase EZH2, a component of the chromatin modifying protein complex PRC2, which is involved in epigenetic silencing via histone methylation (Cao et al., 2002; Hombach and Kretz, 2013; Zhu and Xu, 2013). Kretz et al. illustrated that lncRNA TINCR (terminal differentiation induced non-coding RNA) is upregulated in epidermal differentiation and forms a complex with STAU1 (staufen double-stranded RNA binding protein), which increases stabilization of differentiation (Kretz et al., 2013). Together, DANCR and TINCR are essential in maintaining epidermal homeostasis (Hombach and Kretz, 2013; Kretz et al., 2013) in cells under normal state, however their
behaviors in inflammatory skin conditions are not well studied. Another study that focused on the roles of lncRNAs in cutaneous biology demonstrated that lncRNA BC020554 is downregulated while AK022798 is upregulated during keratinocyte differentiation (Tang et al., 2020). However, for the majority of the skin-expressing lncRNAs, there is limited information regarding their biological and pathological roles in cutaneous disorders.

Psoriasis is a chronic, relapsing, hyperproliferative, inflammatory skin disease whereby the epidermis is thickened secondary to abnormal differentiation of basal keratinocytes (Szegedi et al., 2010; Tang et al., 2020). LncRNA PRINS (psoriasis susceptibility related RNA gene induced by stress) has been shown to contribute to psoriasis susceptibility and is overexpressed in psoriatic uninvolved skin (Sonkoly et al., 2005; Zenz et al., 2005; Bari et al., 2011; Szegedi et al., 2012; Hombach and Kretz, 2013; Tsoi et al., 2015). It is also involved in cellular stress response and may play a role in psoriasis by decreasing sensitivity to keratinocyte apoptosis via the regulation of G1P3 (Sonkoly et al., 2005; Zenz et al., 2005; Bari et al., 2011; Szegedi et al., 2012). Ma et al. demonstrated that lncRNA UCA1 (urothelial carcinoma-associated 1) was downregulated in psoriatic lesional skin (Ma et al., 2021). Initially named for its high expression in bladder cancer cells (Roberson and Bowcock, 2010; Ma et al., 2021), UCA1 has now gained more attention regarding its role in psoriasis (Ma et al., 2021). Specifically, it upregulates the expression of cytoplasmic zinc finger protein A20 (TNFAIP3, TNFα induced protein 3) by inhibiting microRNA125a (Ma et al., 2021). Through the miRNA125a-A20 axis, UCA1 negatively regulates the activity of NFκB (Li et al., 2015; Ma et al., 2021). Other lncRNAs that have revealed roles in psoriasis include lncRNA RP6-65G23.1, lncRNA MXY2P (cytoplasmic lncRNA Msh homeobox 2 pseudogene 1), and lncRNA GASS (growth arrest specific 5). LncRNA RP6-65G23.1 is upregulated in psoriatic keratinocytes and associated with increased anti-apoptotic cells (i.e., BCL2 and Bcl-xl) and cell proliferation (Lizzul et al., 2005; Duan et al., 2020). LncRNA MXY2P is also upregulated in psoriatic lesional skin (Kretz et al., 2013) and involved in IL-22 induced keratinocyte growth. LncRNA GASS is a strong indicator of psoriasis severity (Ahmed Shehata et al., 2021). While these studies have helped to gather biological insight for these newly uncovered lncRNAs, the reported expression profiles are sometimes ambiguous (see below), and there is no comprehensive catalog regarding most skin-expressing lncRNAs’ biological and pathological roles.

Therefore, in this review we aim to characterize the expression profiles for the prominent skin-expressing lncRNAs, aiming to provide additional insights for their potential roles in atopic dermatitis and psoriasis pathology by integrating in vitro, in vivo, and in silico techniques. First, we identified candidate lncRNAs that were previously identified in the literature to play a role in cutaneous biology. We then evaluated the gene expression patterns in in vivo lesional atopic dermatitis and psoriasis skin to identify the differentially expressed lncRNAs (Tsoi et al., 2019a; Tsoi et al., 2019b). We evaluated the lncRNA profiles from published transcriptomes in non-lesional and lesional skin from 27 atopic dermatitis and 28 psoriatic patients, as well as from 38 healthy controls. This information was integrated with in vitro genomics data of cytokine-stimulated conditions (IFNα, IFNγ, IL-4, IL-13, IL-17A, IL-17 + TNFα, TNFα) from 40 patients to infer the regulatory mechanism upon inflammatory response for keratinocytes (Tsoi et al., 2019a; Tsoi et al., 2019b). We also conducted correlation analysis for the in vivo and in vitro data to associate expression profiles of the candidate lncRNAs with the other prominent genes involved in skin inflammation. To reveal lncRNA-expressing cell type in the in vivo data, we assayed the expressions in scRNA-seq data from non-lesional and lesional skin.

### Differentially Expressed lncRNAs in Cytokine Stimulated Keratinocytes and In-Vivo Lesional Skin

The summary statistics for the above lncRNAs detected in our analysis were presented in Table 1. As previously discussed, DANCR and TINCR play critical roles in maintaining epidermal homeostasis (Huarte et al., 2010; Kretz et al., 2012). DANCR is expressed in non-differentiating keratinocytes while TINCR is expressed in differentiating keratinocytes (Piipponen et al., 2020). When evaluating gene expression patterns in lesional compared to control skin, DANCR was upregulated and TINCR was downregulated in psoriasis lesional skin (Figure 1A). These findings support our current understanding of psoriasis as an inflammatory skin disease that is in part characterized by poor differentiation of keratinocytes (Ma et al., 2021). Of importance, we discovered that TINCR was also downregulated in atopic dermatitis lesional skin—a finding that has not previously been reported. Similar to TINCR, lncRNA H19 also regulates keratinocyte differentiation by targeting MiR-130b-3p and inhibiting its activity on Desmoglein 1 (Dsg1) (Li et al., 2017), which is expressed mainly in the superficial layer of the epidermis and mediates cell-cell adhesion. We found that H19 was downregulated in both atopic dermatitis (Fold Change FC = 0.31; FDR = 3.26*10^{-6}) and psoriasis (Fold Change FC = 0.05; FDR = 3.34*10^{-7}) lesional skin, and it was also depleted in the IFN and IL17/TNF stimulated keratinocytes, further supporting our understanding of aberrant differentiation of keratinocytes in many skin diseases, such as psoriasis and atopic dermatitis (Li et al., 2017; Tang et al., 2020).

Prominent skin-expressing lncRNAs that were upregulated in both psoriasis and atopic dermatitis lesional skin include UCA1 and SPRRC2C (small proline rich protein 2C) (Table 1). Through the miRNA125a-A20 axis, UCA1 has been shown to downregulate NFκB which plays an important role in linking psoriatic keratinocytes and immune cell states (Ma et al., 2021). However, UCA1 has previously been reported to be downregulated in psoriatic keratinocytes (Ma et al., 2021) for patients with elevated NFκB signaling. Our analysis therefore suggests heterogeneity in inflammatory signaling among psoriatic patients, in concordance with our recent findings that show the association between variations in molecular signature and anti-TNF drug response (Tsoi et al., 2021). Indeed, we observed that UCA1 can be associated with NFκB signaling (see correlation analysis below). SPRRC2C has also been shown to play an important role in psoriasis pathogenesis and response to
treatment (Luo et al., 2021). Prior studies have indicated that it is upregulated in psoriasis lesion skin (Luo et al., 2021), consistent with our analysis (Table 1; Figure 1A). Moreover, though with a lesser degree than that in lesional skin, SPRR2C is significantly upregulated in both the non-lesional skin of psoriasis and atopic dermatitis (Figure 1A), and it is also induced through IL17 and IL17 + TNF stimulation in keratinocytes; while the dysregulation of UCA1 was also observed in the lesional skin but not the non-lesional skin of AD and psoriasis. While many of the more notable lncRNAs listed in Table 1 do not seem to respond significantly to cytokine stimulation of keratinocytes, previous studies have highlighted a substantial portion (~40%) of all the >1,000 skin-expressing lncRNAs are dysregulated in the lesional skin of psoriasis and atopic dermatitis (Tsoi et al., 2015; Tsoi et al., 2019b), suggesting that we still have very limited knowledge in understanding potential biological regulation and roles for this type of transcript.

CO-EXPRESSSION ANALYSIS REVEALED POTENTIAL BIOLOGICAL MODULES

Our previous work utilized co-expression patterns to infer potential biological roles of lncRNAs (Tsoi et al., 2015). In this study, we also found significant correlations between the
aforementioned lncRNAs with other genes known to play roles in skin diseases (Figure 1B). For instances, we observed strong negative correlation ($r = -0.75, p = 8 \times 10^{-77}$) between H19 and CYP1A1 in keratinocytes. In addition to its important impact on drug metabolism (Mescher and Haarmann-Stemmann, 2018), CYP1A1 is involved in the AHR pathway, which controls skin barrier homeostasis (Kyoreva et al., 2021). Meanwhile, SPRR2C is positively correlated with other genes encoding for small proline-rich proteins (i.e., SPRR2D, SPRR2B, SPRR2G), which are structural components of the cornified epithelia; and it is also correlated with IL36A ($r = 0.55, p = 8 \times 10^{-33}$), IL36G ($r = 0.58, p = 5 \times 10^{-37}$) and IL36RN ($r = 0.57, p = 5 \times 10^{-36}$), a group of cytokines which are involved in skin inflammation (not shown in Figure 1B) (Hernández-Santana et al., 2020) and contribute to the pathogenesis of psoriasis and atopic dermatitis (Tsang et al., 2020). Notably, IL-36 signaling has been shown to induce IL-17 and IL-23 signaling (Goldstein et al., 2020), which corresponds with our finding that SPRR2C is up-regulated upon IL-17 stimulation. Other interesting correlations we discovered include UCA1 with filaggrin genes, FLG ($r = 0.84, p = 4 \times 10^{-106}$), FLG2 ($r = 0.82, p = 3 \times 10^{-99}$), as well as late cornified envelope genes, LCE1B ($r = 0.89, p = 7 \times 10^{-141}$), LCE3D ($r = 0.87, p = 4 \times 10^{-127}$), LCE3E ($r = 0.85, p = 1 \times 10^{-116}$), LCE5A ($r = 0.85, p = 7 \times 10^{-115}$). Filaggrin deficiencies are an important risk factor for atopic dermatitis, as they weaken the epidermal barrier (Weidinger et al., 2018). LCE genes, which are associated with psoriasis, have been found to have antibacterial activity (Niehues et al., 2017). Of note, UCA1 was also significantly correlated with TNFSF12A ($r = 0.75, p = 2 \times 10^{-72}$) in keratinocytes, which is an important regulator for the NFκB signaling pathway (Xia et al., 2021).

**Intracellular IncRNA as Cell Type Signature**

We looked up the expression architecture for these lncRNAs in the psoriatic and non-lesional skin scRNA-seq data. Interestingly, despite the well-known cell type specific nature of lncRNAs, we observed that some highly expressed lncRNAs, such as NEAT1, MALAT1, and GAS5 are expressed in all cell types in skin (Figure 2). Others, including UCA1, H19, and TINCR, are expressed only in keratinocytes. However, we were not able to detect SPRR2C, likely due to the lack of sensitivity in detecting low-expressing transcripts for lncRNAs. These lncRNA expression patterns allow us to better understand the cell types that these lncRNAs could exert their functionality. Notably, we observed H19 expression mostly in the basal layer of the epidermis, and the scRNA-seq data further confirmed that it is down-regulated in lesional skin. In comparison, TINCR was found to be expressed in all of the compartments in the epidermal layer. We also replicated the higher expression of UCA1 in the lesional skin of psoriasis, and its expression seems to appear throughout the epidermis while slightly higher in the keratinized layer.

**SUMMARY**

With the advent of next generation sequencing technology, our understanding and characterization of lncRNAs has accelerated (Ponting et al., 2009). As a class, lncRNAs are preferentially enriched in the nucleus, do not have coding protein ability, and exhibit more tissue-specific expression patterns compared to protein-coding genes (Derrien et al., 2012). Over recent years, they have attracted attention due to their roles in epidermal homeostasis, transition to disease states, and stress response (Hombach and Kretz, 2013; Tsol et al., 2015). In this review, we characterized the expression profiles for the prominent skin-expressing lncRNAs and provided additional insights for their potential roles in atopic dermatitis and psoriasis pathology by integrating in vitro, in vivo, and in silico techniques. We were able to
better understand the behaviors for some of the reported skin-specific lncRNAs, as well as their architecture, by integrating single cell RNA-sequencing.

While TINCR is known to play a role in keratinocyte differentiation (Kretz et al., 2013), its dysregulation in atopic dermatitis and psoriasis has not yet been fully understood. Although its downregulation supports our understanding of aberrant differentiation in these diseases (Li et al., 2017), its role in modulating skin differentiation under inflammatory environment require further investigation. Our results also highlight that some of the prominent skin-expressing lncRNAs can be found in multiple different cell types, while others exhibit cell type specific expression patterns. These findings can help us to better understand the cell type specific/shared regulation programming. A higher throughput or transcript-targeted single cell transcriptomic approach can provide a better resolution in revealing expression patterns for more lncRNAs, especially for those that are low-expressing.

In conclusion, this review provided additional insights for the skin-expressing lncRNAs that contribute to atopic dermatitis and psoriasis. It further helped facilitate our understanding of the role of lncRNAs upon cytokine stimulation and how this can relate to autoimmune diseases. We discovered shared and unique expression, as well as cell type specificity, for lncRNAs in non-lesional and lesional skin of psoriatic patients. This analysis should provide valuable information for future studies that target lncRNAs for biomarker development and pharmaceutical intervention.

AUTHOR CONTRIBUTIONS

AS and LT designed and drafted the manuscript. MP, AS, JC, RW, and LT conducted the analysis and literature review. All authors read and approved the work.

FUNDING

This work was supported by the National Psoriasis Foundation (LT, MP, and JG), and awards from the National Institutes of Health (K01AR072129 to LT; 1P30AR075043 to LT, MP, and JG). MP was also supported by the Dermatology Foundation.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fgene.2022.835740/full#supplementary-material

Supplementary Table S1 | Other previously identified lncRNAs that play roles in skin biology and/or diseases.

REFERENCES

Ahmed Shehata, W., Marae, A., Abd El Monem Eliaithy, M., Tayel, N., Abo-Ghazala, A., and Mohammed El-Hefnawy, S. (2021). Circulating Long Noncoding RNA Growth Arrest-specific Transcript 5 as a Diagnostic Marker and Indicator of Degree of Severity in Plaque Psoriasis. Int. J. Dermatol. 60, 973. doi:10.1111/ijd.15494
Bari, L., Bacca, S., Sonkolty, E., Bata-Csorgo, Z., Kemény, L., Dobozy, A., et al. (2011). Comparison of Stress-Induced PRINS Gene Expression in normal Human Keratinocytes and HaCaT Cells. Arch. Dermatol. Res. 303 (10), 745–752. doi:10.1007/s00423-011-1162-8
Bickers, D. R., Lim, H. W., Margolis, D., Weinstock, M. A., Goodman, C., Faulkner, E., et al. (2006). The burden of Skin Diseases: 2004. J. Am. Acad. Dermatol. 55 (3), 490–500. doi:10.1016/j.jaad.2006.05.048
Cao, R., Wang, L., Wang, H., Xia, L., Erdjument-Bromage, H., Tempst, P., et al. (2002). Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing. Science 298 (5595), 1039–1043. doi:10.1126/science.1076997
Derrien, T., Johnson, R., Bussotti, G., Tanzer, A., Djebali, S., Tilgner, H., et al. (2012). The GENCODE V7 Catalog of Human Long Noncoding RNAs: Analysis of Their Gene Structure, Evolution, and Expression. Genome Res. 22 (9), 1775–1789. doi:10.1101/gr.132159.111
Duan, Q., Wang, G., Wang, M., Chen, C., Zhang, M., Liu, M., et al. (2020). LncRNA RP6-65G23.1 Accelerates Proliferation and Inhibits Apoptosis via p-ERK1/2/p- AKT Signaling Pathway on Keratinocytes. J. Cell Biochem. 121 (11), 4580–4589. doi:10.1002/jcb.28685
Fang, S., Zhang, L., Guo, J., Niu, Y., Wu, Y., Li, H., et al. (2018). NONCODEv5: a Comprehensive Annotation Database for Long Non-coding RNAs. Nucleic Acids Res. 46 (D1), D308–D314. doi:10.1093/nar/gkx1107
Frankish, A., Diehmans, M., Jungreis, I., Lagarde, J., Loveland, E. J., Mudge, J. M., et al. (2021). GENCODE 2021. Nucleic Acids Res. 49 (D1), D916–D923. doi:10.1093/nar/gkaa1087
Goldstein, J. D., Bass, O. Y., Caruso, A., Palomo, J., Rodriguez, E., Lemeille, S., et al. (2020). IL-36 Signaling in Keratinocytes Controls Early IL-23 Production in Psoriasis-like Dermatitis. Life Sci. Alliance 3 (6), e202000688. doi:10.26508/lsa.202000688
Gomez, J. A., Wapinski, O. L., Yang, Y. W., Bureau, J.-F., Gopinath, S., Monack, D. M., et al. (2013). The NeST Long ncRNA Controls Microbial Susceptibility and Epigenetic Activation of the Interferon-γ Locus. Cell 152 (4), 743–754. doi:10.1016/j.cell.2013.01.015
Grote, P., Wiltier, L., Hendrix, D., Koch, F., Wahrisch, S., Bießwadel, A., et al. (2013). The Tissue-specific IncRNA Fendr Is an Essential Regulator of Heart and Body wall Development in the Mouse. Dev. Cell 24 (2), 206–214. doi:10.1016/j.devcel.2012.12.012
Gupta, R. A., Shah, N., Wang, K. C., Kim, J., Horlings, H. M., Wong, D. J., et al. (2010). Long Non-coding RNA HOTAIR Reprograms Chromatin State to Promote Cancer Metastasis. Nature 464 (7291), 1071–1076. doi:10.1038/nature08975
Harrow, J., Frankish, A., Gonzalez, J. M., Taparani, E., Diekmans, M., Kokocinski, F., et al. (2012). GENCODE: the Reference Human Genome Annotation for the ENCODE Project. Genome Res. 22 (9), 1760–1774. doi:10.1101/gr.135350.111
Hay, R. I., Augustin, M., Griffiths, C. E. M., and Sterry, W. (2015). The Global challenge for Skin Health. Br. J. Dermatol. 172 (6), 1469–1472. doi:10.1111/bjd.13854
Hay, R. J., Johns, N. E., Williams, H. C., Bolliger, I. W., Delavrille, R. P., Margolis, D. J., et al. (2014). The Global burden of Skin Disease in 2010: an Analysis of the Prevalence and Impact of Skin Conditions. J. Invest. Dermatol. 134 (6), 1527–1534. doi:10.1038/jid.2013.446
Heo, J. B., and Sung, S. (2011). Vernalization-mediated Epigenetic Silencing in Long Intronic Noncoding RNA: Science 331 (6013), 76–79. doi:10.1126/science.1197349
Hernández-Santana, Y. E., Leon, G., St Leger, D., Fallon, P. G., and Walsh, P. T. (2020). Keratinocyte Interleukin-36 Receptor Expression Orchestrates Psoriasis Inflammation in Mice. Life Sci. Alliance 3 (4), e201900586. doi:10.26508/lsa.201900586
Hombach, S., and Kretz, M. (2013). The Non-coding Skin: Exploring the Roles of Long Non-coding RNAs in Epidermal Homeostasis and Disease. Bioessays 35 (12), 1093–1100. doi:10.1002/bies.201300068
Huarte, M., Guttman, M., Feldser, D., Garber, M., Koziol, M. J., Kenzelmann-Broz, F., et al. (2013). The NeST Long ncRNA Induced by P53 Mediates Epigenetic Activation of the Interferon-γ Locus. Cell 152 (4), 743–754. doi:10.1016/j.cell.2013.01.015
Kretz, M., Siprashvili, Z., Chu, C., Webster, D. E., Zehnder, A., Qu, K., et al. (2013). Control of Somatic Tissue Differentiation by the Long Non-coding RNA TINCR. Nature 493 (7431), 231–235. doi:10.1038/nature11661
